Healthcare Business

health care

ELIQUIS Approved for Deep Vein Thrombosis and Pulmonary Embolisms

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) had approved the drug ELIQUIS, as a treatment for Deep Vein Thrombosis and Pulmonary ...
Read Full Story »
biotech

6 Biotech Stocks to Buy Now With Up to 100% Upside Potential

With the biotech space having its usual volatile ups and downs this year, the analysts at Stifel have stepped back into the coverage world and have reinitiated research analysis on ...
Read Full Story »
Stock Split Image

What the Market is Telling MannKind (Updated)

MannKind Corp. (NASDAQ: MNKD) was supposed to be a huge winner on this week's news that Sanofi (NYSE: SNY) will become its global partner for its inhalable insulin Afrezza. There has ...
Read Full Story »
153790263

Is an Impending Implosion of Dendreon Avoidable?

Dendreon Corp. (NASDAQ: DNDN) has turned into one of those unsettling biotech stories: It went from great promise, to high hopes, to a reality check, and now to an incredibly ...
Read Full Story »
Biotechnology word cloud

Short Sellers Vigilant Against Top Biotech Stocks

The short interest report is out for the July 31 settlement date and 247 Wall St. is focusing on the active short selling in the biotech sector. Short sellers are ...
Read Full Story »
186171981

Can Tekmira Make Much Money From Its Ebola Treatment?

Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR) has made a name for itself pioneering new experimental treatments in the wake of the most recent Ebola scare. Ebola is considered one of the deadliest ...
Read Full Story »
research

New Analyst Biotech Stocks to Buy With Gigantic Implied Upside

After being absolutely rocked back in the spring, the biotech sector has bounced back smartly. Even a bubble comment from the head of the Federal Reserve Janet Yellen didn't stop the ...
Read Full Story »
76764023

MannKind Secures Future of Afrezza in Major Sanofi Deal

MannKind Corp. (NASDAQ: MNKD) was supposed to be in the news for its earnings report. Instead, we got news of its strategy on how to get its Afrezza inhalable insulin ...
Read Full Story »
Stock Split Image

Thoratec Implodes on Guidance and Revenue Miss

Thoratec Corp. (NASDAQ: THOR) was the king of the stock drops in Wednesday's after-hours trading session. The reason for its drop of about one-quarter of its value was that its ...
Read Full Story »
DNA

4 Biotech Stocks Where Analysts See 100% Upside, or Even Higher

24/7 Wall St. gets to see what seems like an almost endless number of key Wall Street research reports from analysts at bulge bracket brokerage firms, regional brokerages and boutique ...
Read Full Story »
145922793

5 Affordable Care Act Stock Winners to Buy Now

While many consumers are still struggling mightily with the details of the Affordable Care Act, many of the health services companies involved in the massive plan are finally starting to ...
Read Full Story »
biotech

Should Investors Really Be Chasing Potential Ebola Treatments?

The world is dealing with Ebola outbreaks and scares again. We are also in the midst of debates as to whether two Americans who contracted Ebola in Africa should have been ...
Read Full Story »
Biotechnology word cloud

Do Layoffs in Biotech Send the Right Message?

Investors could be facing a new future in biotech. After years and years of growth and after massive gains in recent years, is it possible that biotech giants are simply ...
Read Full Story »
pills

Drugmakers Merck, Pfizer Eke Out Profit Hikes

Drug giant Merck & Co. Inc. (NYSE: MRK) reported second-quarter 2014 results before markets opened Tuesday. The company posted quarterly adjusted diluted earnings per share (EPS) of $0.85 and revenues ...
Read Full Story »
Pills

AbbVie Earnings Take Back Seat to Shire Merger

AbbVie Inc. (NYSE: ABBV) reported second-quarter 2014 results before markets opened Friday. The pharmaceutical research firm posted adjusted diluted earnings per share (EPS) of $0.82 on revenues of $4.93 billion. ...
Read Full Story »